Chiasma's oral ocreotide controls acromegaly in some patients
This article was originally published in Scrip
Chiasma is raising capital to fund a new drug application (NDA) submission to the US FDA for oral ocreotide in the treatment of acromegaly based on Phase III results that were published on 9 February in the Journal of Clinical Endocrinology and Metabolism (JCEM).
You may also be interested in...
With a near-term launch of Mycapssa unlikely, Chiasma cuts its commercial staff while it evaluates how to respond to an April complete response letter.
BioMarin maintains its lead in the race to win approval for a hemophilia A gene therapy in the US by resubmitting Roctavian two years after the FDA issued a CRL in response to the original BLA.
Eisai and Biogen had double-digit stock price gains based on the positive Phase III readout for lecanemab. The good news also lifted competitors Lilly and Roche as well as earlier-stage Alzheimer’s drug developers.